RecruitingPhase 1Phase 2NCT07110584

Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors

A Phase 1/2, Multi-Center, Open-Label Clinical Study Evaluating MDX2004 In Participants With Advanced Tumors

Sponsor

ModeX Therapeutics, An OPKO Health Company

Enrollment

235 participants

Start Date

Oct 1, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Tumors

Summary

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advanced tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called MDX2004 for people with advanced tumors. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.